Literature DB >> 20138993

The intricate involvement of the Insulin-like growth factor receptor signaling in mild traumatic brain injury in mice.

Vardit Rubovitch1, Shahaf Edut, Rive Sarfstein, Haim Werner, Chaim G Pick.   

Abstract

Insulin-like growth factor-1 (IGF-1) was suggested as a potential neuroprotective treatment for traumatic brain injury (TBI) induced damage (cognitive as well as cellular). The main goal of the present study was to evaluate the role of the IGF-1R activation in spatial memory outcome following mild traumatic brain injury. mTBI-induced phosphorylation of IGF-1R, AKT and ERK1/2, in mice hippocampus, which was inhibited when mice were pretreated with the selective IGF-1R inhibitor AG1024. IGF-1 administration prevented spatial memory deficits following mTBI. Surprisingly, blocking the IGF-1R signaling in mTBI mice did not augment the spatial memory deficit. In addition, this data imply an intriguing and complex role of the IGF-1 signaling axis in the cellular and behavioral events following mTBI. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138993     DOI: 10.1016/j.nbd.2010.01.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  32 in total

1.  Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice.

Authors:  Juyeon Park; Jimmy Zhang; Jianhua Qiu; Xiaoxia Zhu; Alexei Degterev; Eng H Lo; Michael J Whalen
Journal:  J Cereb Blood Flow Metab       Date:  2011-09-21       Impact factor: 6.200

2.  The effect of progesterone dose on gene expression after traumatic brain injury.

Authors:  Gail D Anderson; Federico M Farin; Theo K Bammler; Richard P Beyer; Alicia A Swan; Hui-Wen Wilkerson; Eric D Kantor; Michael R Hoane
Journal:  J Neurotrauma       Date:  2011-09-08       Impact factor: 5.269

3.  Retracted: Involvement of insulin-like growth factor-1 in chemotherapy-related cognitive impairment.

Authors:  Teresita L Briones; Julie Woods; Magdalena Wadowska
Journal:  Behav Brain Res       Date:  2014-03-12       Impact factor: 3.332

4.  The neuroprotective effect of salubrinal in a mouse model of traumatic brain injury.

Authors:  Vardit Rubovitch; Shani Barak; Lital Rachmany; Renana Baratz Goldstein; Yael Zilberstein; Chaim G Pick
Journal:  Neuromolecular Med       Date:  2015-01-13       Impact factor: 3.843

Review 5.  A clinical and pathophysiological approach to traumatic brain injury-induced pituitary dysfunction.

Authors:  Sule Temizkan; Fahrettin Kelestimur
Journal:  Pituitary       Date:  2019-06       Impact factor: 4.107

Review 6.  Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy.

Authors:  Victor S Wong; Brett Langley
Journal:  Neurosci Lett       Date:  2016-05-04       Impact factor: 3.046

7.  Stress-altered synaptic plasticity and DAMP signaling in the hippocampus-PFC axis; elucidating the significance of IGF-1/IGF-1R/CaMKIIα expression in neural changes associated with a prolonged exposure therapy.

Authors:  Olalekan M Ogundele; Philip J Ebenezer; Charles C Lee; Joseph Francis
Journal:  Neuroscience       Date:  2017-04-27       Impact factor: 3.590

8.  Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury.

Authors:  David Tweedie; Lital Rachmany; Vardit Rubovitch; Yongqing Zhang; Kevin G Becker; Evelyn Perez; Barry J Hoffer; Chaim G Pick; Nigel H Greig
Journal:  Neurobiol Dis       Date:  2013-02-27       Impact factor: 5.996

9.  Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice.

Authors:  Xiaoxia Zhu; Juyeon Park; Julianne Golinski; Jianhua Qiu; Jugta Khuman; Christopher C H Lee; Eng H Lo; Alexei Degterev; Michael J Whalen
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

10.  Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.

Authors:  David Tweedie; Lital Rachmany; Vardit Rubovitch; Yazhou Li; Harold W Holloway; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Evelyn Perez; Barry J Hoffer; Chaim G Pick; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2015-08-29       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.